Print

Novavax, Inc. (NVAX) Initiates Phase 2 Clinical Trial of RSV Vaccine Candidate  
10/9/2012 9:32:55 AM

ROCKVILLE, Md., Oct. 8, 2012 (GLOBE NEWSWIRE) -- Novavax, Inc. (Nasdaq:NVAX) today announced that enrollment has begun in a Phase 2 dose-ranging clinical trial of its respiratory syncytial virus (RSV) vaccine candidate in women of childbearing age. The study is being conducted in collaboration with PATH, an international nonprofit organization that transforms global health through innovation, which is providing approximately $2 million in funding to support the trial.
//-->